FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3040968178> ?p ?o ?g. }

• W3040968178 abstract "Abstract Background Progressive multifocal leukoencephalopathy (PML) caused by JC virus (JCV) is a rare but serious complication of some disease-modifying drugs used to treat multiple sclerosis (MS). Japanese MS patients treated with fingolimod were reported to be 10 times more likely to develop PML than equivalent patients in other countries. The strongest susceptibility human leukocyte antigen ( HLA ) class II alleles for MS are distinct between races ( DRB1*15:01 for Caucasians and DRB1*04:05 and DRB1*15:01 for Japanese); therefore, we investigated whether HLA class II alleles modulate anti-JCV antibody serostatus in Japanese MS patients with and without fingolimod. Methods We enrolled 128 Japanese patients with MS, in whom 64 (50%) were under fingolimod treatment at sampling, and examined the relationship between HLA class II alleles and anti-JCV antibody serostatus. Serum anti-JCV antibody positivity and index were measured using a second-generation two-step assay and HLA-DRB1 and -DPB1 alleles were genotyped. Results HLA-DRB1*15 carriers had a lower frequency of anti-JCV antibody positivity (57% vs 78%, p = 0.015), and lower antibody index (median 0.42 vs 1.97, p = 0.037) than non-carriers. Among patients without HLA-DRB1*15 , DRB1*04 carriers had a higher seropositivity rate than non-carriers (84% vs 54%, p = 0.030), and DPB1*04:02 carriers had a higher anti-JCV antibody index than non-carriers (3.20 vs 1.34, p = 0.008) although anti-JCV antibody-positivity rates did not differ. Patients treated with fingolimod had a higher antibody index than other patients (1.46 vs 0.64, p = 0.039) and treatment period had a positive correlation with antibody index ( p = 0.018). Multivariate logistic regression analysis revealed that age was positively associated, and HLA-DRB1*15 was negatively associated with anti-JCV antibody positivity (odds ratio [OR] = 1.06, p = 0.006, and OR = 0.37, p = 0.028, respectively). Excluding HLA-DRB1*15 -carriers, DRB1*04 was an independent risk factor for the presence of anti-JCV antibody (OR = 5.50, p = 0.023). Conclusions HLA-DRB1*15 is associated with low anti-JCV antibody positive rate and low JCV antibody index, and in the absence of DRB1*15 , DRB1*04 carriers are associated with a high antibody positive rate in Japanese, suggesting the effects of two susceptible HLA-DRB1 alleles on anti-JCV antibody serostatus differ." @default.
• W3040968178 created "2020-07-16" @default.
• W3040968178 creator A5005928182 @default.
• W3040968178 creator A5012054982 @default.
• W3040968178 creator A5029405594 @default.
• W3040968178 creator A5033204118 @default.
• W3040968178 creator A5039646427 @default.
• W3040968178 creator A5045391372 @default.
• W3040968178 creator A5057695864 @default.
• W3040968178 creator A5069625228 @default.
• W3040968178 creator A5071700301 @default.
• W3040968178 creator A5075956226 @default.
• W3040968178 date "2020-07-09" @default.
• W3040968178 modified "2023-10-14" @default.
• W3040968178 title "Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod" @default.
• W3040968178 cites W1487904781 @default.
• W3040968178 cites W1967724489 @default.
• W3040968178 cites W1969038254 @default.
• W3040968178 cites W1981625112 @default.
• W3040968178 cites W1983511886 @default.
• W3040968178 cites W1992821990 @default.
• W3040968178 cites W2000019510 @default.
• W3040968178 cites W2006543057 @default.
• W3040968178 cites W2014919600 @default.
• W3040968178 cites W2020670698 @default.
• W3040968178 cites W2022066170 @default.
• W3040968178 cites W2040547343 @default.
• W3040968178 cites W2044022462 @default.
• W3040968178 cites W2045610148 @default.
• W3040968178 cites W2054226526 @default.
• W3040968178 cites W2057350485 @default.
• W3040968178 cites W2064922726 @default.
• W3040968178 cites W2091211345 @default.
• W3040968178 cites W2112165124 @default.
• W3040968178 cites W2116016714 @default.
• W3040968178 cites W2122545833 @default.
• W3040968178 cites W2130730608 @default.
• W3040968178 cites W2140463009 @default.
• W3040968178 cites W2140829906 @default.
• W3040968178 cites W2142404342 @default.
• W3040968178 cites W2153568596 @default.
• W3040968178 cites W2155127563 @default.
• W3040968178 cites W2163435011 @default.
• W3040968178 cites W2164021954 @default.
• W3040968178 cites W2172275967 @default.
• W3040968178 cites W2202821932 @default.
• W3040968178 cites W2260863957 @default.
• W3040968178 cites W2476223773 @default.
• W3040968178 cites W2511351306 @default.
• W3040968178 cites W2566324613 @default.
• W3040968178 cites W2569954169 @default.
• W3040968178 cites W2591976560 @default.
• W3040968178 cites W2759253724 @default.
• W3040968178 cites W2766973650 @default.
• W3040968178 cites W2781689674 @default.
• W3040968178 cites W2789365041 @default.
• W3040968178 cites W2798039679 @default.
• W3040968178 cites W2802030355 @default.
• W3040968178 cites W2891268546 @default.
• W3040968178 cites W2902640859 @default.
• W3040968178 cites W2937883791 @default.
• W3040968178 cites W2964377516 @default.
• W3040968178 doi "https://doi.org/10.1186/s12974-020-01865-7" @default.
• W3040968178 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7350631" @default.
• W3040968178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32646493" @default.
• W3040968178 hasPublicationYear "2020" @default.
• W3040968178 type Work @default.
• W3040968178 sameAs 3040968178 @default.
• W3040968178 citedByCount "5" @default.
• W3040968178 countsByYear W30409681782021 @default.
• W3040968178 countsByYear W30409681782022 @default.
• W3040968178 crossrefType "journal-article" @default.
• W3040968178 hasAuthorship W3040968178A5005928182 @default.
• W3040968178 hasAuthorship W3040968178A5012054982 @default.
• W3040968178 hasAuthorship W3040968178A5029405594 @default.
• W3040968178 hasAuthorship W3040968178A5033204118 @default.
• W3040968178 hasAuthorship W3040968178A5039646427 @default.
• W3040968178 hasAuthorship W3040968178A5045391372 @default.
• W3040968178 hasAuthorship W3040968178A5057695864 @default.
• W3040968178 hasAuthorship W3040968178A5069625228 @default.
• W3040968178 hasAuthorship W3040968178A5071700301 @default.
• W3040968178 hasAuthorship W3040968178A5075956226 @default.
• W3040968178 hasBestOaLocation W30409681781 @default.
• W3040968178 hasConcept C104317684 @default.
• W3040968178 hasConcept C142462285 @default.
• W3040968178 hasConcept C147483822 @default.
• W3040968178 hasConcept C159047783 @default.
• W3040968178 hasConcept C159654299 @default.
• W3040968178 hasConcept C180754005 @default.
• W3040968178 hasConcept C188280979 @default.
• W3040968178 hasConcept C203014093 @default.
• W3040968178 hasConcept C2522874641 @default.
• W3040968178 hasConcept C2776036978 @default.
• W3040968178 hasConcept C2776535787 @default.
• W3040968178 hasConcept C2779150272 @default.
• W3040968178 hasConcept C2780640218 @default.
• W3040968178 hasConcept C2780644213 @default.
• W3040968178 hasConcept C54355233 @default.
• W3040968178 hasConcept C71924100 @default.
• W3040968178 hasConcept C86803240 @default.

• next